Alzamend Neuro Files 8-K with Bylaw Amendments

TL;DR

Alzamend Neuro filed an 8-K on 3/7/24 for bylaw changes and exhibits.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on March 7, 2024, reporting amendments to its Articles of Incorporation or Bylaws and including financial statements and exhibits. The company, incorporated in Delaware, is based in Atlanta, GA, and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates potential changes in the company's governance or operational structure, which could impact its strategic direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine procedural update and does not contain information about significant financial distress or major operational shifts.

Key Numbers

• 001-40483 — SEC File Number (Identifies the company's filing history with the SEC.)
• 81-1822909 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Alzamend Neuro, Inc. (company) — Registrant
• March 7, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Atlanta, GA (location) — Principal executive offices
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M

Filing Documents

• g362408k.htm (8-K) — 27KB
• ex3_1.htm (EX-3.1) — 64KB
• ex3_2.htm (EX-3.2) — 8KB
• exex31-001.jpg (GRAPHIC) — 50KB
• exex31-002.jpg (GRAPHIC) — 182KB
• exex31-003.jpg (GRAPHIC) — 168KB
• exex31-004.jpg (GRAPHIC) — 184KB
• exex31-005.jpg (GRAPHIC) — 240KB
• exex31-006.jpg (GRAPHIC) — 241KB
• exex31-007.jpg (GRAPHIC) — 259KB
• exex31-008.jpg (GRAPHIC) — 288KB
• exex31-009.jpg (GRAPHIC) — 256KB
• exex31-010.jpg (GRAPHIC) — 259KB
• exex31-011.jpg (GRAPHIC) — 73KB
• exex31-012.jpg (GRAPHIC) — 27KB
• exex31-013.jpg (GRAPHIC) — 64KB
• exex32-001.jpg (GRAPHIC) — 50KB
• exex32-002.jpg (GRAPHIC) — 191KB
• exex32-003.jpg (GRAPHIC) — 26KB
• 0001214659-24-004200.txt ( ) — 3823KB
• alzn-20240307.xsd (EX-101.SCH) — 3KB
• alzn-20240307_lab.xml (EX-101.LAB) — 33KB
• alzn-20240307_pre.xml (EX-101.PRE) — 22KB
• g362408k_htm.xml (XML) — 4KB

03 Amendments to Articles of Incorporation or Bylaws; Change In Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change In Fiscal Year. As previously reported on Current Report Form 8-K filed on February 2, 2024, on January 31, 2024, Alzamend Neuro, Inc., a Delaware corporation (the " Company "), filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the " Original Certificate of Designations "). On March 1, 2024, the Company filed with the Secretary of State of the state of Delaware an Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the " Amended and Restated Certificate of Designations "). The Amended and Restated Certificate of Designations amended and restated the Original Certificate of Designations to correct all references from Series A Preferred Stock to Series B Preferred Stock and clarified the voting rights of the Series B convertible preferred stock, par value $0.0001 per share (" Series B Convertible Preferred Stock ") in accordance with the rules of the Nasdaq Stock Market. No other amendments were made to the preferences and rights of the Series B Convertible Preferred Stock. The foregoing description of the Amended and Restated Certificate of Designations is qualified in its entirety by reference to the complete Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock of Alzamend Neuro, Inc., a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference. Additionally, on March 1, 2024, the Company filed with the Secretary of State of the state of Delaware, a Certificate of Elimination of the Certificate of Designations of Preferred Stock of Alzamend Neuro, Inc. (the " Certificate of Elimination "), with respect to the Company's Series A convertible preferred stock, par value $0.0001 per share (" Series A Convertible Preferred Stock "). The Ce

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 3.1 Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 1, 2024. 3.2 Certificate of Elimination of the Series A Convertible Preferred Stock of Alzamend Neuro, Inc. 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: March 7, 2024 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel -3-

View Full Filing

View this 8-K filing on SEC EDGAR